查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
放射性藥物市場規模和預測、全球和區域佔有率、趨勢和成長機會分析報告範圍：按應用、類型、示踪劑類型、最終用戶和地理位置
市場調查報告書
商品編碼
1498536

放射性藥物市場規模和預測、全球和區域佔有率、趨勢和成長機會分析報告範圍：按應用、類型、示踪劑類型、最終用戶和地理位置

Radiopharmaceuticals Market Size and Forecast, Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Application, Type, Tracer Type, End User, and Geography
出版日期: | 出版商: The Insight Partners | 英文 237 Pages | 訂單完成後即時交付

價格

放射性藥物市場規模預計將從2023年的90.7億美元激增至2031年的265.1億美元；預計 2023 年至 2031 年市場複合年成長率為 14.4%。慢性病盛行率的上升和標靶治療臨床試驗數量的增加推動了放射性藥物市場的成長。

放射性藥物已被證明可以有效診斷和治療與年齡相關的疾病。放射性藥物的開發具有改進的靶向能力、更長的半衰期和更少的副作用，這使得它們對各種應用更具吸引力。將診斷和治療功能結合在單一放射性藥物中的治療診斷學研究前景廣闊，可以進一步推動市場成長。隨著世界各國政府認知到放射性藥物在改善健康結果方面的價值，新放射性藥物的研究和開發資金以及批准其支持性監管途徑的資金增加。此外，市場正在朝著滿足不斷變化的醫療保健環境的需求的方向發展，並且使用先進診斷技術的不斷發展的放射性製藥設施預計將在未來幾年帶來新的放射性藥物市場趨勢。

慢性病盛行率上升推動放射性藥物市場

肺病、癌症、中風、阿茲海默症、心血管疾病（CVD）、慢性腎臟病和各種神經系統疾病等慢性疾病在世界各地迅速增加。根據世界衛生組織 (WHO) 統計，2020 年，全球約有 1,000 萬人因癌症死亡。同樣，根據美國癌症協會的估計，2020 年，美國新診斷出約 1,806,590 例癌症病例。根據 2020 年國家癌症登記計畫報告，印度報告了 679,421 例男性癌症病例，預計到 2025 年將增加至約 763,575 例；而在女性中，2020年記錄了712,758例癌症病例，預計到2025年這一數字將達到806,218例。男性12,540例）被記錄下來。心血管疾病是最常見的慢性疾病類型之一，死亡率很高。美國疾病管制與預防中心表示，心臟病是美國的首要死因。據同一消息來源稱，2020 年，美國約有 697,000 人死亡，即五分之一的死亡是由心臟病引起的。據帕金森氏症基金會稱，帕金森氏症症狀通常出現在 60 歲及以上的人群中。加拿大心理學會指出，加拿大約有2%的人口患有強迫症。根據世界衛生組織的數據，神經系統疾病佔全球疾病負擔的 6.3%，也是全球死亡的主要原因之一。據報導，已開發國家和低收入和中等收入國家的死亡人數分別有 13.2% 和 16.8% 是由神經系統疾病引起的。放射性藥物已被證明在診斷神經系統和神經退化性疾病以及肌肉骨骼疾病方面具有高效性。放射性藥物因其雙重功能而與眾不同。它們不僅增強了疾病的可視化，還提供了重要的功能資訊。在各種可用的方法中，放射性同位素細胞標記是追蹤細胞以研究其生物分佈的最有前途的技術之一。因此，慢性病發病率的飆升正在推動放射性藥物市場的成長。

市場趨勢

不斷發展的放射性藥物設施

核子醫學是一個正在經歷許多變化的領域。隨著放射性藥物的快速發展，PET 和放射治療等更先進的診斷技術正在得到更廣泛的應用。在低收入國家，由於國際原子能機構（IAEA）的努力，該技術仍在建立中，而在美國等一些技術先進國家，該技術正在演變成標準護理，特別是隨著治療診斷的出現。

一些非洲國家正在原子能機構技術合作規劃和協調研究計畫的幫助下，努力擴大其放射性藥物設施並使其現代化，以生產放射性藥物。例如，在國際原子能總署的支持下，北非國家突尼斯開始使用PET。同時，在阿爾及利亞，一台醫用迴旋加速器安裝並投入運作。該機器使該國能夠生產放射性藥物，並能夠對淋巴瘤、肺癌和結腸癌等多種癌症進行常規 PET 成像。

放射性藥物趨勢國際研討會展示了放射性藥物化學和核子醫學的光明前景。同位素生產、放射化學以及新型放射性藥物在人體研究中的應用的進步帶來了令人興奮的結果。特別是，使用影像指導標靶治療的治療診斷策略以及不斷發展的研究領域正在幫助全球核子醫學界透過開發新的放射治療方法實現個人化醫療的潛力。治療診斷學將診斷和治療融為一體。放射性示蹤劑可識別特定目標（診斷），然後進行標靶治療。這種方法可以讓醫生透過即時評估患者對治療的反應來為患者制定個人化治療計劃。治療診斷對於治療某些形式的癌症特別有希望，例如前列腺癌和神經內分泌腫瘤。借助新的放射性示蹤劑和顯影劑，分子影像變得更加特異和靈敏，從而能夠更早、更準確地檢測疾病。此外，混合影像（例如 PET-CT 和 PET-MRI）結合了兩種或多種影像模式，以提供互補資訊並提高診斷準確性。這些方法結合了功能和解剖訊息，能夠全面概述疾病過程。因此，此類發展和方法預計將推動未來的市場成長。

「全球放射性藥物市場」根據應用、示蹤劑類型、最終用戶和地理位置進行細分。

基於應用程式的見解

根據應用，放射性藥物市場分析是透過考慮以下細分市場進行的：腫瘤學、心臟病學、神經學、肺病學、泌尿學等。腫瘤學領域在 2023 年佔據最大的市場佔有率，預計在預測期內複合年成長率最高為 14.8%。癌症是死亡率較高的主要健康問題之一。根據世界衛生組織的數據，2020 年，全球估計新診斷出 1,010 萬癌症病例，1,000 萬人死於癌症。癌症患者的診斷和治療需要影像學檢查以確保準確的管理決策和最佳結果。核子醫學療法用於治療癌症，最常見的放射性追蹤劑是F-18氟脫氧葡萄糖（FDG）。 FDG與葡萄糖相似，癌細胞代謝較活躍；因此，它們以更高的速度吸收葡萄糖。這可以在 PET 掃描中看到，從而使醫療保健專業人員能夠檢測到疾病。標記為氟脫氧葡萄糖的氟-i8 可有效區分惡性與良性腫瘤以及確定疾病的程度。 2018 年 1 月 FDA 批准镥 Lu 177 dotatate (Lutathera) 後，神經內分泌腫瘤 (NET) 患者可以更廣泛地接受 PRRT。

基於最終用戶的見解

按最終用戶分類，市場分為醫院和診所、診斷中心、學術和研究機構等。 2023 年，醫院和診所領域在放射性藥物市場佔有率中佔據主導地位。醫院和診所利用技術先進的方法治療心臟動脈瘤、腫瘤腫瘤、神經動脈瘤和其他治療程序。對心血管和神經動脈瘤治療的需求不斷成長已成為推動醫院和診所市場成長的主要因素之一。由於持續的患者護理和監測，大多數手術都在醫院進行。

美國食品藥物管理局、歐盟、世界衛生組織、國際原子能機構、疾病管制與預防中心、國家癌症研究所、國家醫療產品管理局、經濟合作暨發展組織和加拿大核安委員會等準備放射性藥物市場研究報告時參考的相關來源。

目錄

第 1 章：簡介

第 2 章：執行摘要

  • 重要見解

第 3 章：研究方法

  • 覆蓋範圍
  • 二次研究
  • 初步研究

第 4 章：放射性藥物市場格局

  • 概述
  • PEST分析
  • 定價分析
    • 區域定價分析，美元（每劑）

第 5 章：放射性藥物市場 - 主要市場動態

  • 放射性藥物市場 - 主要市場動態
  • 市場促進因素
    • 慢性病盛行率上升
    • 標靶治療的臨床試驗數量不斷增加
  • 市場限制
    • 放射性藥物的保存期限短
  • 市場機會
    • 發展中國家的高成長潛力
  • 未來的趨勢
    • 不斷發展的放射性藥物設施
  • 促進因素和限制的影響：

第 6 章：放射性藥物市場 - 全球市場分析

  • 放射性藥物市場收入，2023-2031

第 7 章：放射性藥物市場分析 - 按應用

  • 概述
  • 腫瘤學
  • 心臟病學
  • 神經病學
  • 肺部
  • 泌尿科
  • 其他

第 8 章：放射性藥物市場分析 - 按類型

  • 概述
  • 診斷
  • 治療性

第 9 章：放射性藥物市場分析 - 按示蹤劑類型

  • 概述
  • Tc-99m
  • F-18
  • Ga-68
  • TL-201
  • I-131
  • 鐵59
  • 盧-171
  • RB-82 和 N-13
  • Cr-51 和 P-32
  • SC-46
  • SG-269 和 Hs-269
  • 其他

第 10 章：放射性藥物市場分析 - 按最終用戶

  • 概述
  • 醫院和診所
  • 診斷中心
  • 學術及研究機構
  • 其他

第 11 章：放射性藥物市場 - 地理分析

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 歐洲其他地區
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 澳洲
    • 韓國
    • 亞太地區其他地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 南非
    • 阿拉伯聯合大公國
    • 中東和非洲其他地區
  • 南美洲和中美洲
    • 巴西
    • 阿根廷
    • 南美洲和中美洲其他地區

第 12 章：放射性藥物市場-產業格局

  • 概述
  • 放射性藥物市場的成長策略
  • 無機成長策略
    • 概述
  • 有機成長策略
    • 概述

第 13 章：公司簡介

  • Cardinal Health Inc
  • Curium
  • General Electric Co
  • Medi-Radiopharma
  • Rotem Industries Ltd
  • ABX advanced biochemical compounds GmbH
  • Invicro LLC
  • Newcastle University
  • Novartis AG
  • Blue Earth Diagnostics Limited
  • IBA Radiopharma Solutions

第 14 章：附錄

Product Code: TIPRE00003751

The radiopharmaceuticals market size is projected to surge from US$ 9.07 billion in 2023 to US$ 26.51 billion by 2031; the market is estimated to record a CAGR of 14.4% during 2023-2031. The rising prevalence of chronic diseases and the growing number of clinical trials in targeted therapy propel the radiopharmaceuticals market growth.

Radiopharmaceuticals have proven to handle the diagnosis and treatment of age-related diseases efficiently. The development of radiopharmaceuticals with improved targeting capabilities, longer half-lives, and fewer side effects makes them more attractive for various applications. Research into theranostics that combine diagnostic and therapeutic functions in a single radiopharmaceutical is promising and could further drive the market growth. As governments across the world recognize the value of radiopharmaceuticals in improving health outcomes, an increase in the funding for research and development of new radiopharmaceuticals and supportive regulatory pathways for their approval has been observed. Further, the market is progressing toward meeting the demands of a changing healthcare landscape, and the evolving radiopharmacy facilities using advanced diagnostic techniques are expected to bring new radiopharmaceuticals market trends in the coming years.

Rising Prevalence of Chronic Diseases Drives the Radiopharmaceuticals Market

Chronic diseases such as lung diseases, cancer, stroke, Alzheimer's, cardiovascular diseases (CVDs), chronic kidney disease, and various neurological disorders are increasing swiftly across the world. As per the World Health Organization (WHO), in 2020, ~10 million deaths were reported due to cancer globally. Likewise, as per the estimations of the American Cancer Society, in 2020, ~1,806,590 new cases of cancer were diagnosed in the US. As per the National Cancer Registry Program Report 2020, in India, 679,421 cancer cases were reported in males, and the number is anticipated to increase to ~763,575 by 2025; whereas in females, 712,758 cancer cases were recorded in 2020, and the number is predicted to reach 806,218 by 2025. According to the American Cancer Society's report, in 2023, ~43,720 new cases of thyroid cancer (31,180 in women and 12,540 in men) were recorded. CVDs are among the most prevalent types of chronic diseases that result in a high mortality rate. The Centers for Disease Control and Prevention states that heart disease is the leading cause of death in the US. According to the same source, in 2020, ~697,000 deaths, i.e., 1 in 5 deaths, were caused by heart disease in the US. According to the Parkinson's Foundation, Parkinson's symptoms are usually observed in individuals aged 60 years and above. The Canadian Psychological Association states that about 2% of the population in Canada suffers from obsessive-compulsive disorder. As per the WHO, neurological diseases contribute to 6.3% of the global disease burden and are also among the leading causes of death worldwide. 13.2% and 16.8% of deaths are reported due to neurological diseases in developed and low- and middle-income countries, respectively. Radiopharmaceuticals have been demonstrated to have high efficiency in diagnosing neurological and neurodegenerative disorders and musculoskeletal conditions. Radiopharmaceuticals are set apart due to their dual functionality. They not only enhance the visualization of diseases but also provide crucial functional information. Among the various methods available, radioisotope cell labeling is one of the most promising techniques to track cells to investigate their biodistribution. Thus, the surging incidence of chronic diseases is driving the radiopharmaceuticals market growth.

Market Trend

Evolving Radiopharmacy Facilities

Nuclear medicine is a field that is undergoing many changes. As radiopharmaceuticals evolve rapidly, more advanced diagnostic techniques such as PET and radiotherapeutics are becoming more widely used. In low-income countries, the technology is still being established, owing to the efforts by the International Atomic Energy Agency (IAEA), while in some of the technologically advanced countries such as the US, it is evolving into standard care, particularly with the advent of theranostics.

Several African countries are working toward expanding and modernizing their radiopharmaceutical facilities to produce radiopharmaceutical medicines with the help of IAEA's Technical Cooperation Program and coordinated research projects. For instance, with IAEA's support, Tunisia, a country in North Africa, started using PET. At the same time, in Algeria, a medical cyclotron was installed and commissioned. The machine enables the country to produce its radiopharmaceuticals and enables routine PET imaging for many types of cancer, such as lymphoma and lung and colon cancer.

The International Symposium on Trends in Radiopharmaceuticals showcases the bright future of radiopharmaceutical chemistry and nuclear medicine. Advances in isotope production, radiochemistry, and the implementation of novel radiopharmaceuticals in human studies lead to exciting results. In particular, theranostic strategies, which use imaging to guide targeted therapy, and the growing areas of research are helping the global nuclear medicine community realize the potential of personalized medicine through the development of new radiotherapeutics. Theranostics merges diagnostics and therapy in a single approach. Radioactive tracers identify specific targets (diagnosis) and then perform targeted therapies. This approach lets physicians personalize treatment plans for patients by assessing their response to therapy in real time. Theranostics are particularly promising for the treatment of certain forms of cancer, such as prostate cancer and neuroendocrine tumors. With new radiotracers and imaging agents, molecular imaging is becoming more specific and sensitive, enabling earlier and more accurate disease detection. In addition, hybrid imaging, such as PET-CT and PET-MRI, combines two or more imaging modalities to provide complementary information and improve diagnostic accuracy. These approaches combine functional and anatomical information, enabling a comprehensive overview of disease processes. Therefore, such developments and approaches are expected to drive the market growth in the future.

The "Global Radiopharmaceuticals Market" is segmented on the basis of application, tracer type, end user, and geography.

Application-Based Insights

Based on application, the radiopharmaceuticals market analysis is carried out by considering the following segments: oncology, cardiology, neurology, pulmonary, urology, and others. The oncology segment held the largest market share in 2023 and is anticipated to register the highest CAGR of 14.8% during the forecast period. Cancer is one of the major health problems with a high mortality rate. As per the WHO, in 2020, an estimated 10.1 million new cancer cases were diagnosed, and 10 million people died from cancer worldwide. The diagnosis and treatment of patients with cancer require access to imaging to ensure accurate management decisions and optimal outcomes. Nuclear medicine therapy is used to treat cancer, and the most common radiotracer is F-18 fluorodeoxyglucose (FDG). FDG is similar to glucose, and cancer cells are more metabolically active; therefore, they absorb glucose at a higher rate. This can be seen on PET scans and thereby allows the healthcare professional to detect the disease. Fluorine-i8 labeled as flurodeoxyglucose is effective in differentiating malignant from benign tumors and in determining the extent of the disease. People with neuroendocrine tumors (NETs) have wider access to PRRT following the FDA approval of lutetium Lu 177 dotatate (Lutathera) in January 2018.

End User-Based Insights

By end user, the market is segmented into hospitals and clinics, diagnostic centers, academic and research institutes, and others. The hospitals and clinics segment dominated the radiopharmaceuticals market share in 2023. The diagnostic centers segment is anticipated to register the highest CAGR of 14.8% during 2023-2031. Hospitals and clinics utilize technologically advanced treatment for cardiac aneurysms, oncology tumors, neurology aneurysms, and other treatment procedures. The growing need for cardiovascular and neurology aneurysm treatments has become one of the major factors driving the market growth for the hospitals and clinics segment. Most of the surgeries are being performed in hospitals, owing to the continuous patient care and monitoring.

US Food and Drug Administration, European Union, World Health Organization, International Atomic Energy Agency, Centers For Disease Control And Prevention, National Cancer Institute, National Medical Products Administration, Organization For Economic Co-Operation And Development, and Canadian Nuclear Safety Commission are some of the relevant sources referred while preparing the radiopharmaceuticals market research report.

Table Of Contents

1. Introduction

  • 1.1 The Insight Partners Research Report Guidance
  • 1.2 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights

3. Research Methodology

  • 3.1 Coverage
  • 3.2 Secondary Research
  • 3.3 Primary Research

4. Radiopharmaceuticals Market Landscape

  • 4.1 Overview
  • 4.2 PEST Analysis
  • 4.3 Pricing Analysis
    • 4.3.1 Regional Pricing Analysis, US$ (Per Dose)

5. Radiopharmaceuticals Market - Key Market Dynamics

  • 5.1 Radiopharmaceuticals Market - Key Market Dynamics
  • 5.2 Market Drivers
    • 5.2.1 Rising Prevalence of Chronic Diseases
    • 5.2.2 Growing Number of Clinical Trials in Targeted Therapy
  • 5.3 Market Restraints
    • 5.3.1 Short Shelf-Life of Radiopharmaceuticals
  • 5.4 Market Opportunities
    • 5.4.1 High Growth Potential in Developing Countries
  • 5.5 Future Trends
    • 5.5.1 Evolving Radiopharmacy Facilities
  • 5.6 Impact of Drivers and Restraints:

6. Radiopharmaceuticals Market - Global Market Analysis

  • 6.1 Radiopharmaceuticals Market Revenue (US$ Million), 2023-2031

7. Radiopharmaceuticals Market Analysis - by Application

  • 7.1 Overview
  • 7.2 Oncology
    • 7.2.1 Overview
    • 7.2.2 Oncology: Radiopharmaceuticals Market - Revenue and Forecast to 2031 (US$ Million)
  • 7.3 Cardiology
    • 7.3.1 Overview
    • 7.3.2 Cardiology: Radiopharmaceuticals Market - Revenue and Forecast to 2031 (US$ Million)
  • 7.4 Neurology
    • 7.4.1 Overview
    • 7.4.2 Neurology: Radiopharmaceuticals Market - Revenue and Forecast to 2031 (US$ Million)
  • 7.5 Pulmonary
    • 7.5.1 Overview
    • 7.5.2 Pulmonary: Radiopharmaceuticals Market - Revenue and Forecast to 2031 (US$ Million)
  • 7.6 Urology
    • 7.6.1 Overview
    • 7.6.2 Urology: Radiopharmaceuticals Market - Revenue and Forecast to 2031 (US$ Million)
  • 7.7 Others
    • 7.7.1 Overview
    • 7.7.2 Others: Radiopharmaceuticals Market - Revenue and Forecast to 2031 (US$ Million)

8. Radiopharmaceuticals Market Analysis - by Type

  • 8.1 Overview
  • 8.2 Diagnostic
    • 8.2.1 Overview
    • 8.2.2 Diagnostic: Radiopharmaceuticals Market - Revenue and Forecast to 2031 (US$ Million)
      • 8.2.2.1 Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - By Diagnostic
  • 8.3 Therapeutic
    • 8.3.1 Overview
    • 8.3.2 Therapeutic: Radiopharmaceuticals Market - Revenue and Forecast to 2031 (US$ Million)
      • 8.3.2.1 Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - By Therapeutic

9. Radiopharmaceuticals Market Analysis - by Tracer Type

  • 9.1 Overview
  • 9.2 Tc-99m
    • 9.2.1 Overview
    • 9.2.2 Tc-99m: Radiopharmaceuticals Market - Revenue and Forecast to 2031 (US$ Million)
      • 9.2.2.1 Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - By Tc-99m
  • 9.3 F-18
    • 9.3.1 Overview
    • 9.3.2 F-18: Radiopharmaceuticals Market - Revenue and Forecast to 2031 (US$ Million)
  • 9.4 Ga-68
    • 9.4.1 Overview
    • 9.4.2 Ga-68: Radiopharmaceuticals Market - Revenue and Forecast to 2031 (US$ Million)
  • 9.5 TL-201
    • 9.5.1 Overview
    • 9.5.2 TL-201: Radiopharmaceuticals Market - Revenue and Forecast to 2031 (US$ Million)
  • 9.6 I-131
    • 9.6.1 Overview
    • 9.6.2 I-131: Radiopharmaceuticals Market - Revenue and Forecast to 2031 (US$ Million)
  • 9.7 Fe-59
    • 9.7.1 Overview
    • 9.7.2 Fe-59: Radiopharmaceuticals Market - Revenue and Forecast to 2031 (US$ Million)
  • 9.8 Lu-171
    • 9.8.1 Overview
    • 9.8.2 Lu-171: Radiopharmaceuticals Market - Revenue and Forecast to 2031 (US$ Million)
  • 9.9 RB-82 and N-13
    • 9.9.1 Overview
    • 9.9.2 RB-82 and N-13: Radiopharmaceuticals Market - Revenue and Forecast to 2031 (US$ Million)
  • 9.10 Cr-51 and P-32
    • 9.10.1 Overview
    • 9.10.2 Cr-51 and P-32: Radiopharmaceuticals Market - Revenue and Forecast to 2031 (US$ Million)
  • 9.11 Sc-46
    • 9.11.1 Overview
    • 9.11.2 Sc-46: Radiopharmaceuticals Market - Revenue and Forecast to 2031 (US$ Million)
  • 9.12 Sg-269 and Hs-269
    • 9.12.1 Overview
    • 9.12.2 Sg-269 and Hs-269: Radiopharmaceuticals Market - Revenue and Forecast to 2031 (US$ Million)
  • 9.13 Others
    • 9.13.1 Overview
    • 9.13.2 Others: Radiopharmaceuticals Market - Revenue and Forecast to 2031 (US$ Million)

10. Radiopharmaceuticals Market Analysis - by End User

  • 10.1 Overview
  • 10.2 Hospitals and Clinics
    • 10.2.1 Overview
    • 10.2.2 Hospitals and Clinics: Radiopharmaceuticals Market - Revenue and Forecast to 2031 (US$ Million)
  • 10.3 Diagnostic Centers
    • 10.3.1 Overview
    • 10.3.2 Diagnostic Centers: Radiopharmaceuticals Market - Revenue and Forecast to 2031 (US$ Million)
  • 10.4 Academic and Research Institutes
    • 10.4.1 Overview
    • 10.4.2 Academic and Research Institutes: Radiopharmaceuticals Market - Revenue and Forecast to 2031 (US$ Million)
  • 10.5 Others
    • 10.5.1 Overview
    • 10.5.2 Others: Radiopharmaceuticals Market - Revenue and Forecast to 2031 (US$ Million)

11. Radiopharmaceuticals Market - Geographical Analysis

  • 11.1 Overview
  • 11.2 North America
    • 11.2.1 North America Radiopharmaceuticals Market Overview
    • 11.2.2 North America: Radiopharmaceuticals Market - Revenue and Forecast to 2031 (US$ Million)
    • 11.2.3 North America: Radiopharmaceuticals Market - Revenue and Forecast Analysis - by Application
    • 11.2.4 North America: Radiopharmaceuticals Market - Revenue and Forecast Analysis - by Type
      • 11.2.4.1 North America: Radiopharmaceuticals Market - Revenue and Forecast Analysis - by Diagnostic
      • 11.2.4.2 North America: Radiopharmaceuticals Market - Revenue and Forecast Analysis - by Therapeutic
    • 11.2.5 North America: Radiopharmaceuticals Market - Revenue and Forecast Analysis - by Tracer Type
      • 11.2.5.1 North America: Radiopharmaceuticals Market - Revenue and Forecast Analysis - by Tc-99m
    • 11.2.6 North America: Radiopharmaceuticals Market - Revenue and Forecast Analysis - by End User
    • 11.2.7 North America: Radiopharmaceuticals Market - Revenue and Forecast Analysis - by Country
      • 11.2.7.1 United States: Radiopharmaceuticals Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.2.7.1.1 United States: Radiopharmaceuticals Market Breakdown, by Application
        • 11.2.7.1.2 United States: Radiopharmaceuticals Market Breakdown, by Type
        • 11.2.7.1.2.1 United States: Radiopharmaceuticals Market Breakdown, by Diagnostic
        • 11.2.7.1.2.2 United States: Radiopharmaceuticals Market Breakdown, by Therapeutic
        • 11.2.7.1.3 United States: Radiopharmaceuticals Market Breakdown, by Tracer Type
        • 11.2.7.1.3.1 United States: Radiopharmaceuticals Market Breakdown, by Tc-99m
        • 11.2.7.1.4 United States: Radiopharmaceuticals Market Breakdown, by End User
      • 11.2.7.2 Canada: Radiopharmaceuticals Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.2.7.2.1 Canada: Radiopharmaceuticals Market Breakdown, by Application
        • 11.2.7.2.2 Canada: Radiopharmaceuticals Market Breakdown, by Type
        • 11.2.7.2.2.1 Canada: Radiopharmaceuticals Market Breakdown, by Diagnostic
        • 11.2.7.2.2.2 Canada: Radiopharmaceuticals Market Breakdown, by Therapeutic
        • 11.2.7.2.3 Canada: Radiopharmaceuticals Market Breakdown, by Tracer Type
        • 11.2.7.2.3.1 Canada: Radiopharmaceuticals Market Breakdown, by Tc-99m
        • 11.2.7.2.4 Canada: Radiopharmaceuticals Market Breakdown, by End User
      • 11.2.7.3 Mexico: Radiopharmaceuticals Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.2.7.3.1 Mexico: Radiopharmaceuticals Market Breakdown, by Application
        • 11.2.7.3.2 Mexico: Radiopharmaceuticals Market Breakdown, by Type
        • 11.2.7.3.2.1 Mexico: Radiopharmaceuticals Market Breakdown, by Diagnostic
        • 11.2.7.3.2.2 Mexico: Radiopharmaceuticals Market Breakdown, by Therapeutic
        • 11.2.7.3.3 Mexico: Radiopharmaceuticals Market Breakdown, by Tracer Type
        • 11.2.7.3.3.1 Mexico: Radiopharmaceuticals Market Breakdown, by Tc-99m
        • 11.2.7.3.4 Mexico: Radiopharmaceuticals Market Breakdown, by End User
  • 11.3 Europe
    • 11.3.1 Europe Radiopharmaceuticals Market Overview
    • 11.3.2 Europe: Radiopharmaceuticals Market - Revenue and Forecast to 2031 (US$ Million)
    • 11.3.3 Europe: Radiopharmaceuticals Market - Revenue and Forecast Analysis - by Application
    • 11.3.4 Europe: Radiopharmaceuticals Market - Revenue and Forecast Analysis - by Type
      • 11.3.4.1 Europe: Radiopharmaceuticals Market - Revenue and Forecast Analysis - by Diagnostic
      • 11.3.4.2 Europe: Radiopharmaceuticals Market - Revenue and Forecast Analysis - by Therapeutic
    • 11.3.5 Europe: Radiopharmaceuticals Market - Revenue and Forecast Analysis - by Tracer Type
      • 11.3.5.1 Europe: Radiopharmaceuticals Market - Revenue and Forecast Analysis - by Tc-99m
    • 11.3.6 Europe: Radiopharmaceuticals Market - Revenue and Forecast Analysis - by End User
    • 11.3.7 Europe: Radiopharmaceuticals Market - Revenue and Forecast Analysis - by Country
      • 11.3.7.1 Germany: Radiopharmaceuticals Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.3.7.1.1 Germany: Radiopharmaceuticals Market Breakdown, by Application
        • 11.3.7.1.2 Germany: Radiopharmaceuticals Market Breakdown, by Type
        • 11.3.7.1.2.1 Germany: Radiopharmaceuticals Market Breakdown, by Diagnostic
        • 11.3.7.1.2.2 Germany: Radiopharmaceuticals Market Breakdown, by Therapeutic
        • 11.3.7.1.3 Germany: Radiopharmaceuticals Market Breakdown, by Tracer Type
        • 11.3.7.1.3.1 Germany: Radiopharmaceuticals Market Breakdown, by Tc-99m
        • 11.3.7.1.4 Germany: Radiopharmaceuticals Market Breakdown, by End User
      • 11.3.7.2 United Kingdom: Radiopharmaceuticals Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.3.7.2.1 United Kingdom: Radiopharmaceuticals Market Breakdown, by Application
        • 11.3.7.2.2 United Kingdom: Radiopharmaceuticals Market Breakdown, by Type
        • 11.3.7.2.2.1 United Kingdom: Radiopharmaceuticals Market Breakdown, by Diagnostic
        • 11.3.7.2.2.2 United Kingdom: Radiopharmaceuticals Market Breakdown, by Therapeutic
        • 11.3.7.2.3 United Kingdom: Radiopharmaceuticals Market Breakdown, by Tracer Type
        • 11.3.7.2.3.1 United Kingdom: Radiopharmaceuticals Market Breakdown, by Tc-99m
        • 11.3.7.2.4 United Kingdom: Radiopharmaceuticals Market Breakdown, by End User
      • 11.3.7.3 France: Radiopharmaceuticals Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.3.7.3.1 France: Radiopharmaceuticals Market Breakdown, by Application
        • 11.3.7.3.2 France: Radiopharmaceuticals Market Breakdown, by Type
        • 11.3.7.3.2.1 France: Radiopharmaceuticals Market Breakdown, by Diagnostic
        • 11.3.7.3.2.2 France: Radiopharmaceuticals Market Breakdown, by Therapeutic
        • 11.3.7.3.3 France: Radiopharmaceuticals Market Breakdown, by Tracer Type
        • 11.3.7.3.3.1 France: Radiopharmaceuticals Market Breakdown, by Tc-99m
        • 11.3.7.3.4 France: Radiopharmaceuticals Market Breakdown, by End User
      • 11.3.7.4 Italy: Radiopharmaceuticals Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.3.7.4.1 Italy: Radiopharmaceuticals Market Breakdown, by Application
        • 11.3.7.4.2 Italy: Radiopharmaceuticals Market Breakdown, by Type
        • 11.3.7.4.2.1 Italy: Radiopharmaceuticals Market Breakdown, by Diagnostic
        • 11.3.7.4.2.2 Italy: Radiopharmaceuticals Market Breakdown, by Therapeutic
        • 11.3.7.4.3 Italy: Radiopharmaceuticals Market Breakdown, by Tracer Type
        • 11.3.7.4.3.1 Italy: Radiopharmaceuticals Market Breakdown, by Tc-99m
        • 11.3.7.4.4 Italy: Radiopharmaceuticals Market Breakdown, by End User
      • 11.3.7.5 Spain: Radiopharmaceuticals Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.3.7.5.1 Spain: Radiopharmaceuticals Market Breakdown, by Application
        • 11.3.7.5.2 Spain: Radiopharmaceuticals Market Breakdown, by Type
        • 11.3.7.5.2.1 Spain: Radiopharmaceuticals Market Breakdown, by Diagnostic
        • 11.3.7.5.2.2 Spain: Radiopharmaceuticals Market Breakdown, by Therapeutic
        • 11.3.7.5.3 Spain: Radiopharmaceuticals Market Breakdown, by Tracer Type
        • 11.3.7.5.3.1 Spain: Radiopharmaceuticals Market Breakdown, by Tc-99m
        • 11.3.7.5.4 Spain: Radiopharmaceuticals Market Breakdown, by End User
      • 11.3.7.6 Rest of Europe: Radiopharmaceuticals Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.3.7.6.1 Rest of Europe: Radiopharmaceuticals Market Breakdown, by Application
        • 11.3.7.6.2 Rest of Europe: Radiopharmaceuticals Market Breakdown, by Type
        • 11.3.7.6.2.1 Rest of Europe: Radiopharmaceuticals Market Breakdown, by Diagnostic
        • 11.3.7.6.2.2 Rest of Europe: Radiopharmaceuticals Market Breakdown, by Therapeutic
        • 11.3.7.6.3 Rest of Europe: Radiopharmaceuticals Market Breakdown, by Tracer Type
        • 11.3.7.6.3.1 Rest of Europe: Radiopharmaceuticals Market Breakdown, by Tc-99m
        • 11.3.7.6.4 Rest of Europe: Radiopharmaceuticals Market Breakdown, by End User
  • 11.4 Asia Pacific
    • 11.4.1 Asia Pacific Radiopharmaceuticals Market Overview
    • 11.4.2 Asia Pacific: Radiopharmaceuticals Market - Revenue and Forecast to 2031 (US$ Million)
      • 11.4.2.1 Asia Pacific: Radiopharmaceuticals Market - Revenue and Forecast Analysis - by Application
      • 11.4.2.2 Asia Pacific: Radiopharmaceuticals Market - Revenue and Forecast Analysis - by Type
        • 11.4.2.2.1 Asia Pacific: Radiopharmaceuticals Market - Revenue and Forecast Analysis - by Diagnostic
        • 11.4.2.2.2 Asia Pacific: Radiopharmaceuticals Market - Revenue and Forecast Analysis - by Therapeutic
      • 11.4.2.3 Asia Pacific: Radiopharmaceuticals Market - Revenue and Forecast Analysis - by Tracer Type
        • 11.4.2.3.1 Asia Pacific: Radiopharmaceuticals Market - Revenue and Forecast Analysis - by Tc-99m
      • 11.4.2.4 Asia Pacific: Radiopharmaceuticals Market - Revenue and Forecast Analysis - by End User
    • 11.4.3 Asia Pacific: Radiopharmaceuticals Market - Revenue and Forecast Analysis - by Country
      • 11.4.3.1 China: Radiopharmaceuticals Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.4.3.1.1 China: Radiopharmaceuticals Market Breakdown, by Application
        • 11.4.3.1.2 China: Radiopharmaceuticals Market Breakdown, by Type
        • 11.4.3.1.2.1 China: Radiopharmaceuticals Market Breakdown, by Diagnostic
        • 11.4.3.1.2.2 China: Radiopharmaceuticals Market Breakdown, by Therapeutic
        • 11.4.3.1.3 China: Radiopharmaceuticals Market Breakdown, by Tracer Type
        • 11.4.3.1.3.1 China: Radiopharmaceuticals Market Breakdown, by Tc-99m
        • 11.4.3.1.4 China: Radiopharmaceuticals Market Breakdown, by End User
      • 11.4.3.2 Japan: Radiopharmaceuticals Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.4.3.2.1 Japan: Radiopharmaceuticals Market Breakdown, by Application
        • 11.4.3.2.2 Japan: Radiopharmaceuticals Market Breakdown, by Type
        • 11.4.3.2.2.1 Japan: Radiopharmaceuticals Market Breakdown, by Diagnostic
        • 11.4.3.2.2.2 Japan: Radiopharmaceuticals Market Breakdown, by Therapeutic
        • 11.4.3.2.3 Japan: Radiopharmaceuticals Market Breakdown, by Tracer Type
        • 11.4.3.2.3.1 Japan: Radiopharmaceuticals Market Breakdown, by Tc-99m
        • 11.4.3.2.4 Japan: Radiopharmaceuticals Market Breakdown, by End User
      • 11.4.3.3 India: Radiopharmaceuticals Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.4.3.3.1 India: Radiopharmaceuticals Market Breakdown, by Application
        • 11.4.3.3.2 India: Radiopharmaceuticals Market Breakdown, by Type
        • 11.4.3.3.2.1 India: Radiopharmaceuticals Market Breakdown, by Diagnostic
        • 11.4.3.3.2.2 India: Radiopharmaceuticals Market Breakdown, by Therapeutic
        • 11.4.3.3.3 India: Radiopharmaceuticals Market Breakdown, by Tracer Type
        • 11.4.3.3.3.1 India: Radiopharmaceuticals Market Breakdown, by Tc-99m
        • 11.4.3.3.4 India: Radiopharmaceuticals Market Breakdown, by End User
      • 11.4.3.4 Australia: Radiopharmaceuticals Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.4.3.4.1 Australia: Radiopharmaceuticals Market Breakdown, by Application
        • 11.4.3.4.2 Australia: Radiopharmaceuticals Market Breakdown, by Type
        • 11.4.3.4.2.1 Australia: Radiopharmaceuticals Market Breakdown, by Diagnostic
        • 11.4.3.4.2.2 Australia: Radiopharmaceuticals Market Breakdown, by Therapeutic
        • 11.4.3.4.3 Australia: Radiopharmaceuticals Market Breakdown, by Tracer Type
        • 11.4.3.4.3.1 Australia: Radiopharmaceuticals Market Breakdown, by Tc-99m
        • 11.4.3.4.4 Australia: Radiopharmaceuticals Market Breakdown, by End User
      • 11.4.3.5 South Korea: Radiopharmaceuticals Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.4.3.5.1 South Korea: Radiopharmaceuticals Market Breakdown, by Application
        • 11.4.3.5.2 South Korea: Radiopharmaceuticals Market Breakdown, by Type
        • 11.4.3.5.2.1 South Korea: Radiopharmaceuticals Market Breakdown, by Diagnostic
        • 11.4.3.5.2.2 South Korea: Radiopharmaceuticals Market Breakdown, by Therapeutic
        • 11.4.3.5.3 South Korea: Radiopharmaceuticals Market Breakdown, by Tracer Type
        • 11.4.3.5.3.1 South Korea: Radiopharmaceuticals Market Breakdown, by Tc-99m
        • 11.4.3.5.4 South Korea: Radiopharmaceuticals Market Breakdown, by End User
      • 11.4.3.6 Rest of APAC: Radiopharmaceuticals Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.4.3.6.1 Rest of APAC: Radiopharmaceuticals Market Breakdown, by Application
        • 11.4.3.6.2 Rest of APAC: Radiopharmaceuticals Market Breakdown, by Type
        • 11.4.3.6.2.1 Rest of APAC: Radiopharmaceuticals Market Breakdown, by Diagnostic
        • 11.4.3.6.2.2 Rest of APAC: Radiopharmaceuticals Market Breakdown, by Therapeutic
        • 11.4.3.6.3 Rest of APAC: Radiopharmaceuticals Market Breakdown, by Tracer Type
        • 11.4.3.6.3.1 Rest of APAC: Radiopharmaceuticals Market Breakdown, by Tc-99m
        • 11.4.3.6.4 Rest of APAC: Radiopharmaceuticals Market Breakdown, by End User
  • 11.5 Middle East and Africa
    • 11.5.1 Middle East and Africa Radiopharmaceuticals Market Overview
    • 11.5.2 Middle East and Africa: Radiopharmaceuticals Market - Revenue and Forecast to 2031 (US$ Million)
      • 11.5.2.1 Middle East and Africa: Radiopharmaceuticals Market - Revenue and Forecast Analysis - by Application
      • 11.5.2.2 Middle East and Africa: Radiopharmaceuticals Market - Revenue and Forecast Analysis - by Type
        • 11.5.2.2.1 Middle East and Africa: Radiopharmaceuticals Market - Revenue and Forecast Analysis - by Diagnostic
        • 11.5.2.2.2 Middle East and Africa: Radiopharmaceuticals Market - Revenue and Forecast Analysis - by Therapeutic
      • 11.5.2.3 Middle East and Africa: Radiopharmaceuticals Market - Revenue and Forecast Analysis - by Tracer Type
        • 11.5.2.3.1 Middle East and Africa: Radiopharmaceuticals Market - Revenue and Forecast Analysis - by Tc-99m
      • 11.5.2.4 Middle East and Africa: Radiopharmaceuticals Market - Revenue and Forecast Analysis - by End User
    • 11.5.3 Middle East and Africa: Radiopharmaceuticals Market - Revenue and Forecast Analysis - by Country
      • 11.5.3.1 Saudi Arabia: Radiopharmaceuticals Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.5.3.1.1 Saudi Arabia: Radiopharmaceuticals Market Breakdown, by Application
        • 11.5.3.1.2 Saudi Arabia: Radiopharmaceuticals Market Breakdown, by Type
        • 11.5.3.1.2.1 Saudi Arabia: Radiopharmaceuticals Market Breakdown, by Diagnostic
        • 11.5.3.1.2.2 Saudi Arabia: Radiopharmaceuticals Market Breakdown, by Therapeutic
        • 11.5.3.1.3 Saudi Arabia: Radiopharmaceuticals Market Breakdown, by Tracer Type
        • 11.5.3.1.3.1 Saudi Arabia: Radiopharmaceuticals Market Breakdown, by Tc-99m
        • 11.5.3.1.4 Saudi Arabia: Radiopharmaceuticals Market Breakdown, by End User
      • 11.5.3.2 South Africa: Radiopharmaceuticals Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.5.3.2.1 South Africa: Radiopharmaceuticals Market Breakdown, by Application
        • 11.5.3.2.2 South Africa: Radiopharmaceuticals Market Breakdown, by Type
        • 11.5.3.2.2.1 South Africa: Radiopharmaceuticals Market Breakdown, by Diagnostic
        • 11.5.3.2.2.2 South Africa: Radiopharmaceuticals Market Breakdown, by Therapeutic
        • 11.5.3.2.3 South Africa: Radiopharmaceuticals Market Breakdown, by Tracer Type
        • 11.5.3.2.3.1 South Africa: Radiopharmaceuticals Market Breakdown, by Tc-99m
        • 11.5.3.2.4 South Africa: Radiopharmaceuticals Market Breakdown, by End User
      • 11.5.3.3 United Arab Emirates: Radiopharmaceuticals Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.5.3.3.1 United Arab Emirates: Radiopharmaceuticals Market Breakdown, by Application
        • 11.5.3.3.2 United Arab Emirates: Radiopharmaceuticals Market Breakdown, by Type
        • 11.5.3.3.2.1 United Arab Emirates: Radiopharmaceuticals Market Breakdown, by Diagnostic
        • 11.5.3.3.2.2 United Arab Emirates: Radiopharmaceuticals Market Breakdown, by Therapeutic
        • 11.5.3.3.3 United Arab Emirates: Radiopharmaceuticals Market Breakdown, by Tracer Type
        • 11.5.3.3.3.1 United Arab Emirates: Radiopharmaceuticals Market Breakdown, by Tc-99m
        • 11.5.3.3.4 United Arab Emirates: Radiopharmaceuticals Market Breakdown, by End User
      • 11.5.3.4 Rest of Middle East and Africa: Radiopharmaceuticals Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.5.3.4.1 Rest of Middle East and Africa: Radiopharmaceuticals Market Breakdown, by Application
        • 11.5.3.4.2 Rest of Middle East and Africa: Radiopharmaceuticals Market Breakdown, by Type
        • 11.5.3.4.2.1 Rest of Middle East and Africa: Radiopharmaceuticals Market Breakdown, by Diagnostic
        • 11.5.3.4.2.2 Rest of Middle East and Africa: Radiopharmaceuticals Market Breakdown, by Therapeutic
        • 11.5.3.4.3 Rest of Middle East and Africa: Radiopharmaceuticals Market Breakdown, by Tracer Type
        • 11.5.3.4.3.1 Rest of Middle East and Africa: Radiopharmaceuticals Market Breakdown, by Tc-99m
        • 11.5.3.4.4 Rest of Middle East and Africa: Radiopharmaceuticals Market Breakdown, by End User
  • 11.6 South and Central America
    • 11.6.1 South and Central America Radiopharmaceuticals Market Overview
    • 11.6.2 South and Central America: Radiopharmaceuticals Market - Revenue and Forecast to 2031 (US$ Million)
      • 11.6.2.1 South and Central America: Radiopharmaceuticals Market - Revenue and Forecast Analysis - by Application
      • 11.6.2.2 South and Central America: Radiopharmaceuticals Market - Revenue and Forecast Analysis - by Type
        • 11.6.2.2.1 South and Central America: Radiopharmaceuticals Market - Revenue and Forecast Analysis - by Diagnostic
        • 11.6.2.2.2 South and Central America: Radiopharmaceuticals Market - Revenue and Forecast Analysis - by Therapeutic
      • 11.6.2.3 South and Central America: Radiopharmaceuticals Market - Revenue and Forecast Analysis - by Tracer Type
        • 11.6.2.3.1 South and Central America: Radiopharmaceuticals Market - Revenue and Forecast Analysis - by Tc-99m
      • 11.6.2.4 South and Central America: Radiopharmaceuticals Market - Revenue and Forecast Analysis - by End User
    • 11.6.3 South and Central America: Radiopharmaceuticals Market - Revenue and Forecast Analysis - by Country
      • 11.6.3.1 Brazil: Radiopharmaceuticals Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.6.3.1.1 Brazil: Radiopharmaceuticals Market Breakdown, by Application
        • 11.6.3.1.2 Brazil: Radiopharmaceuticals Market Breakdown, by Type
        • 11.6.3.1.2.1 Brazil: Radiopharmaceuticals Market Breakdown, by Diagnostic
        • 11.6.3.1.2.2 Brazil: Radiopharmaceuticals Market Breakdown, by Therapeutic
        • 11.6.3.1.3 Brazil: Radiopharmaceuticals Market Breakdown, by Tracer Type
        • 11.6.3.1.3.1 Brazil: Radiopharmaceuticals Market Breakdown, by Tc-99m
        • 11.6.3.1.4 Brazil: Radiopharmaceuticals Market Breakdown, by End User
      • 11.6.3.2 Argentina: Radiopharmaceuticals Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.6.3.2.1 Argentina: Radiopharmaceuticals Market Breakdown, by Application
        • 11.6.3.2.2 Argentina: Radiopharmaceuticals Market Breakdown, by Type
        • 11.6.3.2.2.1 Argentina: Radiopharmaceuticals Market Breakdown, by Diagnostic
        • 11.6.3.2.2.2 Argentina: Radiopharmaceuticals Market Breakdown, by Therapeutic
        • 11.6.3.2.3 Argentina: Radiopharmaceuticals Market Breakdown, by Tracer Type
        • 11.6.3.2.3.1 Argentina: Radiopharmaceuticals Market Breakdown, by Tc-99m
        • 11.6.3.2.4 Argentina: Radiopharmaceuticals Market Breakdown, by End User
      • 11.6.3.3 Rest of South and Central America: Radiopharmaceuticals Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.6.3.3.1 Rest of South and Central America: Radiopharmaceuticals Market Breakdown, by Application
        • 11.6.3.3.2 Rest of South and Central America: Radiopharmaceuticals Market Breakdown, by Type
        • 11.6.3.3.2.1 Rest of South and Central America: Radiopharmaceuticals Market Breakdown, by Diagnostic
        • 11.6.3.3.2.2 Rest of South and Central America: Radiopharmaceuticals Market Breakdown, by Therapeutic
        • 11.6.3.3.3 Rest of South and Central America: Radiopharmaceuticals Market Breakdown, by Tracer Type
        • 11.6.3.3.3.1 Rest of South and Central America: Radiopharmaceuticals Market Breakdown, by Tc-99m
        • 11.6.3.3.4 Rest of South and Central America: Radiopharmaceuticals Market Breakdown, by End User

12. Radiopharmaceuticals Market-Industry Landscape

  • 12.1 Overview
  • 12.2 Growth Strategies in the Radiopharmaceuticals Market
  • 12.3 Inorganic Growth Strategies
    • 12.3.1 Overview
  • 12.4 Organic Growth Strategies
    • 12.4.1 Overview

13. Company Profiles

  • 13.1 Cardinal Health Inc
    • 13.1.1 Key Facts
    • 13.1.2 Business Description
    • 13.1.3 Products and Services
    • 13.1.4 Financial Overview
    • 13.1.5 SWOT Analysis
    • 13.1.6 Key Developments
  • 13.2 Curium
    • 13.2.1 Key Facts
    • 13.2.2 Business Description
    • 13.2.3 Products and Services
    • 13.2.4 Financial Overview
    • 13.2.5 SWOT Analysis
    • 13.2.6 Key Developments
  • 13.3 General Electric Co
    • 13.3.1 Key Facts
    • 13.3.2 Business Description
    • 13.3.3 Products and Services
    • 13.3.4 Financial Overview
    • 13.3.5 SWOT Analysis
    • 13.3.6 Key Developments
  • 13.4 Medi-Radiopharma
    • 13.4.1 Key Facts
    • 13.4.2 Business Description
    • 13.4.3 Products and Services
    • 13.4.4 Financial Overview
    • 13.4.5 SWOT Analysis
    • 13.4.6 Key Developments
  • 13.5 Rotem Industries Ltd
    • 13.5.1 Key Facts
    • 13.5.2 Business Description
    • 13.5.3 Products and Services
    • 13.5.4 Financial Overview
    • 13.5.5 SWOT Analysis
    • 13.5.6 Key Developments
  • 13.6 ABX advanced biochemical compounds GmbH
    • 13.6.1 Key Facts
    • 13.6.2 Business Description
    • 13.6.3 Products and Services
    • 13.6.4 Financial Overview
    • 13.6.5 SWOT Analysis
    • 13.6.6 Key Developments
  • 13.7 Invicro LLC
    • 13.7.1 Key Facts
    • 13.7.2 Business Description
    • 13.7.3 Products and Services
    • 13.7.4 Financial Overview
    • 13.7.5 SWOT Analysis
    • 13.7.6 Key Developments
  • 13.8 Newcastle University
    • 13.8.1 Key Facts
    • 13.8.2 Business Description
    • 13.8.3 Products and Services
    • 13.8.4 Financial Overview
    • 13.8.5 SWOT Analysis
    • 13.8.6 Key Developments
  • 13.9 Novartis AG
    • 13.9.1 Key Facts
    • 13.9.2 Business Description
    • 13.9.3 Products and Services
    • 13.9.4 Financial Overview
    • 13.9.5 SWOT Analysis
    • 13.9.6 Key Developments
  • 13.10 Blue Earth Diagnostics Limited
    • 13.10.1 Key Facts
    • 13.10.2 Business Description
    • 13.10.3 Products and Services
    • 13.10.4 Financial Overview
    • 13.10.5 SWOT Analysis
    • 13.10.6 Key Developments
  • 13.11 IBA Radiopharma Solutions
    • 13.11.1 Key Facts
    • 13.11.2 Business Description
    • 13.11.3 Products and Services
    • 13.11.4 Financial Overview
    • 13.11.5 SWOT Analysis
    • 13.11.6 Key Developments

14. Appendix

  • 14.1 About The Insight Partners
  • 14.2 Glossary of Terms

List Of Tables

  • Table 1. Radiopharmaceuticals Market Segmentation
  • Table 2. Regional Pricing Analysis, US$ (Per Dose), 2023
  • Table 3. Ongoing Targeted Alpha Therapy Clinical Trials
  • Table 4. Physical Half-Lives of Some Medical Radionuclides for Diagnostic and Therapeutic Use
  • Table 5. Some Other Radionuclides Used in Diagnostic Radiopharmaceuticals
  • Table 6. Some Other Radionuclides Used in Therapeutic Radiopharmaceuticals
  • Table 7. Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - By Diagnostic
  • Table 8. Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - By Therapeutic
  • Table 9. Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - By Tc-99m
  • Table 10. North America: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 11. North America: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Type
  • Table 12. North America: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Diagnostic
  • Table 13. North America: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Therapeutic
  • Table 14. North America: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Tracer Type
  • Table 15. North America: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Tc-99m
  • Table 16. North America: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by End User
  • Table 17. United States: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 18. United States: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Type
  • Table 19. United States: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Diagnostic
  • Table 20. United States: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Therapeutic
  • Table 21. United States: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Tracer Type
  • Table 22. United States: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Tc-99m
  • Table 23. United States: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by End User
  • Table 24. Canada: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 25. Canada: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Type
  • Table 26. Canada: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Diagnostic
  • Table 27. Canada: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Therapeutic
  • Table 28. Canada: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Tracer Type
  • Table 29. Canada: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Tc-99m
  • Table 30. Canada: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by End User
  • Table 31. Mexico: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 32. Mexico: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Type
  • Table 33. Mexico: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Diagnostic
  • Table 34. Mexico: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Therapeutic
  • Table 35. Mexico: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Tracer Type
  • Table 36. Mexico: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Tc-99m
  • Table 37. Mexico: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by End User
  • Table 38. Europe: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 39. Europe: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Type
  • Table 40. Europe: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Diagnostic
  • Table 41. Europe: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Therapeutic
  • Table 42. Europe: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Tracer Type
  • Table 43. Europe: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Tc-99m
  • Table 44. Europe: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by End User
  • Table 45. Germany: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 46. Germany: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Type
  • Table 47. Germany: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Diagnostic
  • Table 48. Germany: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Therapeutic
  • Table 49. Germany: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Tracer Type
  • Table 50. Germany: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Tc-99m
  • Table 51. Germany: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by End User
  • Table 52. United Kingdom: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 53. United Kingdom: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Type
  • Table 54. United Kingdom: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Diagnostic
  • Table 55. United Kingdom: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Therapeutic
  • Table 56. United Kingdom: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Tracer Type
  • Table 57. United Kingdom: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Tc-99m
  • Table 58. United Kingdom: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by End User
  • Table 59. France: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 60. France: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Type
  • Table 61. France: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Diagnostic
  • Table 62. France: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Therapeutic
  • Table 63. France: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Tracer Type
  • Table 64. France: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Tc-99m
  • Table 65. France: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by End User
  • Table 66. Italy: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 67. Italy: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Type
  • Table 68. Italy: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Diagnostic
  • Table 69. Italy: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Therapeutic
  • Table 70. Italy: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Tracer Type
  • Table 71. Italy: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Tc-99m
  • Table 72. Italy: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by End User
  • Table 73. Spain: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 74. Spain: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Type
  • Table 75. Spain: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Diagnostic
  • Table 76. Spain: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Therapeutic
  • Table 77. Spain: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Tracer Type
  • Table 78. Spain: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Tc-99m
  • Table 79. Spain: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by End User
  • Table 80. Rest of Europe: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 81. Rest of Europe: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Type
  • Table 82. Rest of Europe: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Diagnostic
  • Table 83. Rest of Europe: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Therapeutic
  • Table 84. Rest of Europe: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Tracer Type
  • Table 85. Rest of Europe: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Tc-99m
  • Table 86. Rest of Europe: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by End User
  • Table 87. Asia Pacific: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 88. Asia Pacific: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Type
  • Table 89. Asia Pacific: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Diagnostic
  • Table 90. Asia Pacific: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Therapeutic
  • Table 91. Asia Pacific: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Tracer Type
  • Table 92. Asia Pacific: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Tc-99m
  • Table 93. Asia Pacific: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by End User
  • Table 94. China: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 95. China: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Type
  • Table 96. China: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Diagnostic
  • Table 97. China: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Therapeutic
  • Table 98. China: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Tracer Type
  • Table 99. China: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Tc-99m
  • Table 100. China: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by End User
  • Table 101. Japan: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 102. Japan: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Type
  • Table 103. Japan: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Diagnostic
  • Table 104. Japan: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Therapeutic
  • Table 105. Japan: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Tracer Type
  • Table 106. Japan: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Tc-99m
  • Table 107. Japan: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by End User
  • Table 108. India: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 109. India: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Type
  • Table 110. India: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Diagnostic
  • Table 111. India: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Therapeutic
  • Table 112. India: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Tracer Type
  • Table 113. India: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Tc-99m
  • Table 114. India: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by End User
  • Table 115. Australia: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 116. Australia: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Type
  • Table 117. Australia: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Diagnostic
  • Table 118. Australia: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Therapeutic
  • Table 119. Australia: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Tracer Type
  • Table 120. Australia: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Tc-99m
  • Table 121. Australia: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by End User
  • Table 122. South Korea: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 123. South Korea: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Type
  • Table 124. South Korea: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Diagnostic
  • Table 125. South Korea: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Therapeutic
  • Table 126. South Korea: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Tracer Type
  • Table 127. South Korea: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Tc-99m
  • Table 128. South Korea: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by End User
  • Table 129. Rest of APAC: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 130. Rest of APAC: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Type
  • Table 131. Rest of APAC: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Diagnostic
  • Table 132. Rest of APAC: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Therapeutic
  • Table 133. Rest of APAC: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Tracer Type
  • Table 134. Rest of APAC: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Tc-99m
  • Table 135. Rest of APAC: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by End User
  • Table 136. Middle East and Africa: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 137. Middle East and Africa: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Type
  • Table 138. Middle East and Africa: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Diagnostic
  • Table 139. Middle East and Africa: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Therapeutic
  • Table 140. Middle East and Africa: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Tracer Type
  • Table 141. Middle East and Africa: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Tc-99m
  • Table 142. Middle East and Africa: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by End User
  • Table 143. Saudi Arabia: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 144. Saudi Arabia: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Type
  • Table 145. Saudi Arabia: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Diagnostic
  • Table 146. Saudi Arabia: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Therapeutic
  • Table 147. Saudi Arabia: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Tracer Type
  • Table 148. Saudi Arabia: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Tc-99m
  • Table 149. Saudi Arabia: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by End User
  • Table 150. South Africa: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 151. South Africa: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Type
  • Table 152. South Africa: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Diagnostic
  • Table 153. South Africa: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Therapeutic
  • Table 154. South Africa: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Tracer Type
  • Table 155. South Africa: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Tc-99m
  • Table 156. South Africa: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by End User
  • Table 157. United Arab Emirates: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 158. United Arab Emirates: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Type
  • Table 159. United Arab Emirates: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Diagnostic
  • Table 160. United Arab Emirates: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Therapeutic
  • Table 161. United Arab Emirates: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Tracer Type
  • Table 162. United Arab Emirates: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Tc-99m
  • Table 163. United Arab Emirates: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by End User
  • Table 164. Rest of Middle East and Africa: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 165. Rest of Middle East and Africa: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Type
  • Table 166. Rest of Middle East and Africa: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Diagnostic
  • Table 167. Rest of Middle East and Africa: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Therapeutic
  • Table 168. Rest of Middle East and Africa: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Tracer Type
  • Table 169. Rest of Middle East and Africa: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Tc-99m
  • Table 170. Rest of Middle East and Africa: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by End User
  • Table 171. South and Central America: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 172. South and Central America: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Type
  • Table 173. South and Central America: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Diagnostic
  • Table 174. South and Central America: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Therapeutic
  • Table 175. South and Central America: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Tracer Type
  • Table 176. South and Central America: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Tc-99m
  • Table 177. South and Central America: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by End User
  • Table 178. Brazil: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 179. Brazil: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Type
  • Table 180. Brazil: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Diagnostic
  • Table 181. Brazil: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Therapeutic
  • Table 182. Brazil: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Tracer Type
  • Table 183. Brazil: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Tc-99m
  • Table 184. Brazil: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by End User
  • Table 185. Argentina: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 186. Argentina: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Type
  • Table 187. Argentina: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Diagnostic
  • Table 188. Argentina: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Therapeutic
  • Table 189. Argentina: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Tracer Type
  • Table 190. Argentina: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Tc-99m
  • Table 191. Argentina: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by End User
  • Table 192. Rest of South and Central America: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 193. Rest of South and Central America: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Type
  • Table 194. Rest of South and Central America: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Diagnostic
  • Table 195. Rest of South and Central America: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Therapeutic
  • Table 196. Rest of South and Central America: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Tracer Type
  • Table 197. Rest of South and Central America: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Tc-99m
  • Table 198. Rest of South and Central America: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by End User
  • Table 199. Recent Inorganic Growth Strategies in the Radiopharmaceuticals Market
  • Table 200. Recent Organic Growth Strategies in the Radiopharmaceuticals Market
  • Table 201. Glossary of Terms, Radiopharmaceuticals Market

List Of Figures

  • Figure 1. Radiopharmaceuticals Market Segmentation, by Geography
  • Figure 2. PEST Analysis
  • Figure 3. Impact Analysis of Drivers and Restraints
  • Figure 4. Radiopharmaceuticals Market Revenue (US$ Million), 2023-2031
  • Figure 5. Bioprocessing Market Breakdown by Geography, 2023 and 2031 (%)
  • Figure 6. Radiopharmaceuticals Market Share (%) - by Application (2023 and 2031)
  • Figure 7. Oncology: Radiopharmaceuticals Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 8. Cardiology: Radiopharmaceuticals Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 9. Neurology: Radiopharmaceuticals Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 10. Pulmonary: Radiopharmaceuticals Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 11. Urology: Radiopharmaceuticals Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 12. Others: Radiopharmaceuticals Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 13. Radiopharmaceuticals Market Share (%) - by Type (2023 and 2031)
  • Figure 14. Diagnostic: Radiopharmaceuticals Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 15. Therapeutic: Radiopharmaceuticals Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 16. Radiopharmaceuticals Market Share (%) - by Tracer Type (2023 and 2031)
  • Figure 17. Tc-99m: Radiopharmaceuticals Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 18. F-18: Radiopharmaceuticals Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 19. Ga-68: Radiopharmaceuticals Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 20. TL-201: Radiopharmaceuticals Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 21. I-131: Radiopharmaceuticals Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 22. Fe-59: Radiopharmaceuticals Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 23. Lu-171: Radiopharmaceuticals Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 24. RB-82 and N-13: Radiopharmaceuticals Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 25. Cr-51 and P-32: Radiopharmaceuticals Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 26. Sc-46: Radiopharmaceuticals Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 27. Sg-269 and Hs-269: Radiopharmaceuticals Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 28. Others: Radiopharmaceuticals Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 29. Radiopharmaceuticals Market Share (%) - by End User (2023 and 2031)
  • Figure 30. Hospitals and Clinics: Radiopharmaceuticals Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 31. Diagnostic Centers: Radiopharmaceuticals Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 32. Academic and Research Institutes: Radiopharmaceuticals Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 33. Others: Radiopharmaceuticals Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 34. Radiopharmaceuticals Market Breakdown by Region, 2023 and 2031 (%)
  • Figure 35. North America: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 36. North America: Radiopharmaceuticals Market Breakdown, by Key Countries, 2023 and 2031 (%)
  • Figure 37. United States: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 38. Canada: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 39. Mexico: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 40. Europe: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 41. Europe: Radiopharmaceuticals Market Breakdown, by Key Countries, 2023 and 2031 (%)
  • Figure 42. Germany: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 43. United Kingdom: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 44. France: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 45. Italy: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 46. Spain: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 47. Rest of Europe: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 48. Asia Pacific: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 49. Asia Pacific: Radiopharmaceuticals Market Breakdown, by Key Countries, 2023 and 2031 (%)
  • Figure 50. China: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 51. Japan: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 52. India: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 53. Australia: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 54. South Korea: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 55. Rest of APAC: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 56. Middle East and Africa: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 57. Middle East and Africa: Radiopharmaceuticals Market Breakdown, by Key Countries, 2023 and 2031 (%)
  • Figure 58. Saudi Arabia: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 59. South Africa: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 60. United Arab Emirates: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 61. Rest of Middle East and Africa: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 62. South and Central America: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 63. South and Central America: Radiopharmaceuticals Market Breakdown, by Key Countries, 2023 and 2031 (%)
  • Figure 64. Brazil: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 65. Argentina: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 66. Rest of South and Central America: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 67. Growth Strategies in the Radiopharmaceuticals Market